Clinical trials
Phase 1 clinical trials
Below are recruiting phase 1 clinical trials, each written for real people, not researchers. We’re tracking 303 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06083883RecruitingPhase 1
NK cell therapy targeting NY-ESO-1 for sarcomas
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
Houston, TexasAges 16–80 - NCT07801820RecruitingPhase 2
Oral diabetes medication study
This study tests an investigational pill for people with type 2 diabetes whose blood sugar is not well controlled despite lifestyle changes or metformin. The pill may help improve blood sugar control and is taken by mouth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07793227RecruitingPhase 3
Testing a new hepatitis A vaccine in healthy people
This trial tests a new hepatitis A vaccine in healthy people aged 1 year and older. It aims to see how well the vaccine prevents hepatitis A and checks for any side effects.
HanoiAges 1 year+ - NCT06526923RecruitingPhase 1/Phase 2
Testing SP-101 gene therapy for cystic fibrosis
This trial tests a new gene therapy called SP-101 for cystic fibrosis. It aims to see if SP-101 is safe and effective for improving lung function.
Kansas City, KansasAges 18–65 - NCT07259538RecruitingPhase 1
Safety study of VVN432 nasal spray
This trial tests a nasal spray called VVN432 in healthy volunteers and people with chronic sinusitis. It checks if the spray is safe and how the body processes it.
BeijingAges 18–55 - NCT06735820RecruitingPhase 1/Phase 2
MEK and MDM2 inhibitors for NF1-related tumors
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07418736RecruitingPhase 2
CM326 for moderate to severe COPD
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
Beijing, Beijing MunicipalityAges 40–85 - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Phoenix, ArizonaAges 1 month–21 years - NCT06942520RecruitingPhase 2
Gene therapy for diabetic macular edema in adults
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
Reno, NevadaAges 25–89 - NCT07619118RecruitingPhase 3
Laroprovstat and rosuvastatin vs. rosuvastatin for high cholesterol
This trial tests whether adding a new medicine, laroprovstat, to a standard cholesterol drug (rosuvastatin) is better at lowering bad cholesterol than the standard drug alone. It might help people who are at high risk for heart disease or stroke.
Sun City West, ArizonaAges 18–130 - NCT06916793RecruitingPhase 3
Study of a new hair loss treatment for men
This study tests an experimental medication (CKD-843) for men with male pattern baldness. It aims to see if the treatment is safe and effective for regrowing hair.
SeoulAges 18–50 - NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT07773246RecruitingPhase 1/Phase 2
Study of KRRO-121 in healthy adults and people with urea cycle disorder
This study tests an investigational drug called KRRO-121. It is first tested in healthy volunteers to check safety, and then in patients with urea cycle disorder (a condition where the body can't remove ammonia properly) to see if it helps.
Melbourne, VictoriaAges 18–65 - NCT05204862RecruitingPhase 1/Phase 2
TU2218 drug with PD-1 therapy for advanced solid tumors
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
San Antonio, TexasAges 18 years+ - NCT07462143RecruitingPhase 2/Phase 3
New drug plus chemo for advanced colorectal cancer
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT01297400RecruitingPhase 2
Testing a topical treatment for thermal burns
This trial studies whether a topical medicine (MW-III) is safe and helps heal thermal burns. It is for adults with relatively limited burn size and certain burn depths, while excluding infected or high-risk wounds.
Phoenix, ArizonaAges 18 years+ - NCT07822646RecruitingPhase 3
Study of a new treatment for advanced ovarian cancer
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07579936RecruitingPhase 2
SAL056 bone-strengthening treatment for postmenopausal osteoporosis
This study tests a new injectable medication called SAL056 to strengthen bones and prevent fractures in postmenopausal women with osteoporosis. Researchers want to find the best dose and how often to give it.
Beijing, Beijing MunicipalityAges 45–80 - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07269782RecruitingPhase 2
Pre-surgery treatment for stage II-III lung cancer
This study tests two investigational drugs (HLX43 and serplulimab) given before surgery to people with stage II to III non-small cell lung cancer (NSCLC). The goal is to see if these drugs can shrink the tumor and make it easier to remove completely during surgery.
ShanghaiAges 18–75 - NCT06857279RecruitingPhase 2
Testing HLX43 for advanced head and neck cancer
This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–75
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 1?
- Yes. Clin2 currently lists 303 recruiting phase 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.